COVID-19 viral disease. Coronavirus infection, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Consumable product includes herbal syrup composed of cyclopeptide fraction with Ziziphus spina-cristi and Pimpinela anisum hydroalcoholic extract and orange peel. T
Sponsors
Bagheiat-allah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: People over the age of 18 who have had close contact with a person with COVID-19 in the last 4 days and signed an informed consent form (close contact is defined as those who live at home with an infected person or depending on their employment situation in Less than two meters away from the infected person.) And have no previous or current history of COVID-19. Age between 18 and 70 years No previous diagnosis of COVID-19 (if possible, test negative for IgG and IgM antibodies.) Absence of symptoms such as fever, body aches, olfactory and taste disturbances, cough, shortness of breath, diarrhea in the last 1 month
Exclusion criteria
Exclusion criteria: Current incidence of COVID-19 is confirmed by PCR and clinical signs. History of autoimmune disease History of rheumatic disease Pregnancy and lactation Age under 18 years People sensitive to any component of the product People who can not follow up. Any clinical reason that may prevent you from entering the study. Do not take two doses of the drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Polymerase chain reaction (PCR) analysis result. Timepoint: At the beginning of the intervention and the day 14. Method of measurement: Polymerase chain reaction (PCR) analysis.;Liver function test result. Timepoint: At the beginning of the intervention and the day 14. Method of measurement: Measurement of aspartate aminotransferase (AST) and Alanine transaminase (ALT) factors.;Fragment D-dimer test result. Timepoint: At the beginning of the intervention and the day 14. Method of measurement: Blood test - Fragment D-dimer measurement.;Measurement of serum iron. Timepoint: At the beginning of the intervention and the day 14. Method of measurement: Blood test - Total iron binding capacity factor (TIBC) measurement.;COVID-19 Antibodies. Timepoint: At the beginning of the intervention and the day 14. Method of measurement: Measurement of IgG COVID-19 and IgM COVID-19 factors. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShiva Shamshiri
Tehran University of Medical Sciences
Outcome results
None listed